Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  He, Lu ^a   Zhou, Xinke ^a   Qu, Chen ^b   Tang, Yunqiang ^a   Zhang, Qiong ^a   Hong, Jian ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma (HCC); Invasion; Prognosis; Serglycin (SRGN)

Indexed keywords

BIOLOGICAL MARKER; PROTEOGLYCAN; SERGLYCIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; TUMOR MARKER; VESICULAR TRANSPORT PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; GENETICS; LIVER TUMOR; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

CADHERINS; CARCINOMA, HEPATOCELLULAR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEOGLYCANS; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS;

EID: 84883112163     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0707-4     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Maluccio M, Covey A, et al. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394-9. doi: 10.3322/caac.21161.
3. Zhu WW, Guo J, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944-54. doi: 10.1158/1078-0432.CCR-12-3363.
4. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757-9. doi: 10.1002/hep.24569.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23(11):1535-47. doi: 10.1111/j.1365-2036.2006.02932.x. (Pubitemid 43727460)
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. doi: 10.1056/NEJMoa0708857.
7. Chen J, Chan AW, To KF, et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology. 2013;57(6):2287-98. doi: 10.1002/hep.26278.
8. Abdel-Rahman O, Abdel-Wahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013;30(3):655. doi: 10.1007/s12032-013-0655-z.
9. Ronnberg E, Pejler G. Serglycin: the master of the mast cell. Methods Mol Biol. 2012;836:201-17. doi: 10.1007/978-1-61779-498-8-14.
10. Woulfe DS, Lilliendahl JK, August S, et al. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood. 2008;111(7):3458-67. doi: 10.1182/blood-2007-07-104703.
11. Glenthoj A, Cowland JB, Heegaard NH, et al. Serglycin participates in retention of alpha-defensin in granules during myelopoiesis. Blood. 2011;118(16):4440-8. doi: 10.1182/blood-2011-06-362947.
12. Henningsson F, Hergeth S, Cortelius R, et al. A role for serglycin proteoglycan in granular retention and processing of mast cell secretory granule components. FEBS J. 2006;273(21):4901-12. doi: 10.1111/j.1742-4658.2006.05489. x. (Pubitemid 44583514)
13. Pejler G, Abrink M, Wernersson S, et al. Serglycin proteoglycan: regulating the storage and activities of hematopoietic proteases. BioFactors (Oxford, England). 2009;35(1):61-8. doi: 10.1002/biof.11.
14. Veugelers K, Motyka B, Frantz C, et al. The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis. Blood. 2004;103(10):3845-53. doi: 10.1182/blood-2003-06-2156. (Pubitemid 38596304)
15. Grujic M, Christensen JP, Sorensen MR, et al. Delayed contraction of the CD8 + T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin. J Immunol. 2008;181(2):1043-51.
16. Kolset SO, Tveit H. Serglycin-structure and biology. Cell Mol Life Sci. 2008;65(7-8):1073-85. doi: 10.1007/s00018-007-7455-6.
17. Meen AJ, Oynebraten I, Reine TM, et al. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J Biol Chem. 2011;286(4):2636-47. doi: 10.1074/jbc.M110.151944.
18. Ho HC, McGrath KE, Brodbeck KC, et al. Serglycin proteoglycan synthesis in the murine uterine decidua and early embryo. Biol Reprod. 2001;64(6):1667-76. (Pubitemid 32493482)
19. Schick BP, Ho HC, Brodbeck KC, et al. Serglycin proteoglycan expression and synthesis in embryonic stem cells. Biochim Biophys Acta. 2003;1593(2-3):259-67. (Pubitemid 36173494)
20. Niemann CU, Kjeldsen L, Ralfkiaer E, et al. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2007;21(12):2406-10. doi: 10.1038/sj.leu.2404975. (Pubitemid 350148881)
21. Scully OJ, Chua PJ, Harve KS, et al. Serglycin in health and diseases. Anat Rec. 2012;295(9):1415-20. doi: 10.1002/ar.22536.
22. Skliris A, Labropoulou VT, Papachristou DJ, et al. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013;280(10):2342-52. doi: 10.1111/febs.12179.
23. Li XJ, Ong CK, Cao Y, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71(8):3162-72. doi: 10.1158/0008-5472.CAN-10-3557.
24. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(18):2586-93. doi: 10.1200/jco.2006.09.4565. (Pubitemid 47041232)
25. Kwon JH, Kim J, Park JY, et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res. 2010;16(22):5511-21. doi: 10.1158/1078-0432.ccr-10- 0825.
26. Ren N, Wu JC, Dong QZ, et al. Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma. Cancer Res. 2011;71(9):3278-86. doi: 10.1158/0008-5472.can-10-3100.
27. Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389. doi: 10.1186/1471-2407-9-389.
28. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711. doi: 10.1093/jnci/djn134.
29. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90. doi: 10.1016/j.cell.2009. 11.007.
30. Liu FY, Deng YL, Li Y, et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol. 2013;30(1):425. doi: 10.1007/s12032-012-0425-3.
31. Zhao D, Yang K, Tang XF, et al. Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial- mesenchymal transition markers and tumor progression. Med Oncol. 2013;30(3):619. doi: 10.1007/s12032-013-0619-3.
32. Schick BP. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog Mol Biol Transl Sci. 2010;93:235-87. doi: 10.1016/s1877-1173(10)93011-1.
33. Theocharis AD, Seidel C, Borset M, et al. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem. 2006;281(46):35116-28. doi: 10.1074/jbc.M601061200. (Pubitemid 46036551)